Idorsia announces
Half Year Results
for 2017
We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Shareprice
Contact
Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland
- +41 58 844 10 10
- Contact us online
Our strategy
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Development pipeline
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
Stay informed
Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.
Financial information
Read all the latest financial information from idorsia.